•
China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has announced clinical clearance from the National Medical Products Administration (NMPA) for its SYH9017, a biosimilar version of Denmark-based Novo Nordisk’s (NYSE: NVO) weight loss drug semaglutide (Ozempic/Wegovy). The clearance allows SYH9017 to proceed to clinical trials focused on weight management for…
•
China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has announced that it has received separate clinical trial approvals from the National Medical Products Administration (NMPA) for its antibody drug conjugates (ADCs), SYS6005 and SYS6043. Pre-Clinical Success and Potential ApplicationsBoth SYS6005 and SYS6043, classified as Category 1 biologic products with undisclosed…
•
CanSino Biologics (SHA: 688185, HKG: 6185) has announced the initiation of a Phase I/II study for its CS-2036, a recombinant polio vaccine, in Indonesia with financial support from the Bill & Melinda Gates Foundation. This development is accompanied by the first subject enrollment in the Phase I trial. Additionally, the…
•
China-based Innovent Biologics, Inc. (HKG: 1801) has announced receiving marketing approval from the National Medical Products Administration (NMPA) for its taletrectinib, a second-generation ROS1 tyrosine kinase inhibitor. The drug is now approved for use in treating adult patients with ROS1 positive locally advanced or metastatic non-small cell lung cancer (NSCLC)…
•
Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has announced receiving marketing approval from the National Medical Products Administration (NMPA) for its FireRaptor coronary rotational atherectomy system. The system includes a rotational atherectomy instrument, disposable coronary artery rotational atherectomy catheter, and rotational atherectomy guide wire. First-Homegrown Coronary Rotational Atherectomy…
•
On December 20, 2024, the China Securities Regulatory Commission confirmed the listing filing for TransThera Sciences (Nanjing), Inc., to proceed with its initial public offering (IPO) in Hong Kong. Proposed Share Issuance and ConversionTransThera Sciences plans to issue up to 146 million overseas-listed ordinary shares on the Hong Kong Stock…
•
Shanghai, China, December 21, 2024 — YolTech Therapeutics today announced that its proprietary in vivo gene-editing drug, YOLT-201, has successfully completed the dose-escalation phase in Phase I clinical trials for the treatment of transthyretin amyloidosis (ATTR) and is set to enter the dose-expansion phase. YOLT-201: A Novel Gene-Editing Therapy for…
•
Wuhan Weike Medical Technology Co., Ltd., known as “Weike Medical,” has officially announced the successful completion of its Series C financing round, raising several hundred million RMB led exclusively by Bohua Capital, a renowned investment institution in Liangxi District, Wuxi. This funding will provide robust financial support for Weike Medical…
•
Japan-based Sumitomo Pharma Co., Ltd (TYO: 4506) has announced an expanded Contract Sales Organization (CSO) collaboration agreement with Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607; SPH). This new agreement follows the success of their initial collaboration in 2020 and aims to further enhance the co-marketing efforts for prescription drugs. Building…
•
US-based Boston Scientific Corporation (NYSE: BSX) has announced that China’s National Medical Products Administration (NMPA) has granted approval for its next-generation intravascular ultrasound (IVUS) diagnostic system, AVVIGO+, for use in diagnosing coronary heart disease. This marks a significant advancement in the diagnostic capabilities for cardiovascular healthcare in China. Multimodal Platform…
•
US-based precision oncology specialist Guardant Health, Inc. (NASDAQ: GH) has entered into an agreement with German pharmaceutical giant Boehringer Ingelheim (BI) to jointly develop and commercialize Guardant360 CDx liquid biopsy as a companion diagnostic (CDx) for zongertinib. This collaboration aims to enhance the treatment landscape for non-small cell lung cancer…
•
Swiss pharmaceutical giant Roche (SWX: ROG) has published results from the Phase IIb PADOVA study for its investigational monoclonal antibody, prasinezumab, in patients with early-stage Parkinson’s disease (PD). The study aimed to assess the drug’s impact on the primary endpoint of time to confirmed motor progression, with a hazard ratio…
•
The Hainan Boao Lecheng International Medical Tourism Pilot Zone, in collaboration with France’s major Sanofi’s (NASDAQ: SNY) China unit and the Paris-Saclay Cancer Cluster (PSCC), has established a tripartite collaboration aimed at advancing healthcare solutions. This partnership is designed to combine the strengths of each organization to enhance the treatment…
•
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced the commercial launch of its sacituzumab tirumotecan (SKB264/MK-2870) in China, marking a significant milestone in the treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who have been previously treated with at least two…
•
China-based Contract Research and Development Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a strategic licensing agreement with compatriot firm Hangzhou DAC Biotechnology Co., Ltd, an antibody drug conjugate (ADC) specialist, and US-based Aadi Bioscience, Inc. (NASDAQ: AADI). The deal grants Aadi Bio global d2018evelopment and commercialization rights to a…
•
China-based gene sequencing specialist MGI Tech Co., Ltd (SHA: 688114) has entered into a strategic partnership with Sabin Group, one of the largest diagnostic laboratories in Brazil. This collaboration aims to enhance the accessibility and quality of genetic sequencing services, thereby improving the healthcare standards for the Brazilian population. Financial…
•
Japan-based Astellas Pharma Inc. (TYO: 4503) has revealed a strategic licensing agreement with US-based Sangamo Therapeutics, Inc. (NASDAQ: SGMO). This collaboration will enable Astellas to utilize Sangamo’s novel proprietary neurotropic adeno-associated virus (AAV) capsid, STAC-BBB, targeting an undisclosed neurological condition. Financial Terms and Potential Impact on Astellas’ PipelineThe agreement allows…
•
Sweden-based BioArctic AB (OTCMKTS: BRCTF) has announced a significant licensing agreement with US pharmaceutical giant Bristol-Myers Squibb (BMS, NYSE: BMY). The deal grants BMS global exclusive development and commercialization rights to BioArctic’s PyroGlutamate-amyloid (PyroGlu-Aβ) antibody program, which includes BAN1503 and BAN2803. Under the agreement, BioArctic retains the option to co-commercialize…
•
China-based Internet healthcare solutions provider Fangzhou Inc. (HKG: 6086) has entered into a partnership with the China unit of US major Bristol-Myers Squibb (BMS, NYSE: BMY). The collaboration, with financial details undisclosed, aims to jointly develop a digital medicine platform and upgrade the Internet health management model, marking a significant…
•
Global healthcare leader Sanofi (NASDAQ: SNY) and China-based Corxel Pharmaceuticals (CORXEL), formerly known as Ji Xing Pharmaceuticals, have jointly announced an official agreement. Under this partnership, Sanofi is set to acquire exclusive development and commercialization rights to CORXEL’s aficamten in Greater China. The financial details of the deal have not…